Use of somatostatin analogues in obesity

Drugs

Volumn 68, Issue 14, 2008, Pages 1963-1973

  Tzotzas, Themistoklis ^a,d   Papazisis, Kostas ^b   Perros, Petros ^c   Krassas, Gerasimos E ^a  

^a PANAGIA GENERAL HOSPITAL   (Greece)

^b Theagenion Medical Institute   (Greece)

^c FREEMAN HOSPITAL   (United Kingdom)

^d NONE   (Greece)

Author keywords

Lanreotide, therapeutic use; Obesity; Octreotide, therapeutic use; Somatostatins, therapeutic use

Indexed keywords

ANGIOPEPTIN; GHRELIN; INSULIN; LONG ACTING DRUG; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 5;

ABDOMINAL PAIN; ADIPOGENESIS; BODY MASS; CHOLELITHIASIS; CLINICAL TRIAL; CRANIOPHARYNGIOMA; DIARRHEA; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENERGY BALANCE; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPHAGIA; HYPOTHALAMIC OBESITY; INSULIN RELEASE; OBESITY; PATHOPHYSIOLOGY; PRADER WILLI SYNDROME; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; CHILD; HORMONE ANTAGONISTS; HUMANS; HYPOTHALAMIC DISEASES; OBESITY; PRADER-WILLI SYNDROME; SOMATOSTATIN;

EID: 51449123652     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868140-00003     Document Type: Review

References (83)

1. Popkin BM, Doak CM. The obesity epidemic is a worldwide phenomenon. Nutr Rev 1998 Apr; 56 (4 Pt 1): 106-14
2. Tzotzas T, Krassas GE. Prevalence and trends of obesity in children and adults of South Europe. Pediatr Endocrinol Rev 2004 Aug; 1 Suppl. 3: 448-54
3. Atkinson RL. Management of obesity: pharmacotherapy. In: Kopelman PG, Caterson LD, Dietz WH, editors. Clinical obesity in adults and children. Malden (MA): Blackwell, 2005: 380-93
4. Mancini MC, Halpern A. Investigational therapies in the treatment of obesity. Expert Opin Investig Drugs 2006 Aug; 15 (8): 897-915
5. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973 Jan; 179 (68): 77-9
6. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997 Jun; 20 (6): 348-67
7. Strowski MZ, Parmar RM, Blake AD, et al. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000 Jan; 141 (1): 111-7
8. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995 Aug; 16 (4): 427-42
9. Lewis I, Bauer W, Albert R, et al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 2003 Jun; 46 (12): 2334-44
10. Stewart PM, James RA. The future of somatostatin analogue therapy. Baillieres Best Pract Res Clin Endocrinol Metab 1999 Oct; 13 (3): 409-18
11. Krassas GE, Tzotzas T, Papazisis K, et al. The efficacy of somatostatin analogues in the treatment of diabetic retinopathy and thyroid eye disease. Clin Ophthalmol 2007; 1 (3): 209-15
12. Lamberts SW, Van der Lely AJ, De Herder WW, et al. Octreotide. N Engl J Med 1996 Jan; 334 (4): 246-54
13. Pliquett RU, Führer D, Falk S, et al. The effects of insulin on the central nervous system: focus on appetite regulation. Horm Metab Res 2006 Jul; 38 (7): 442-6
14. Niswender KD, Schwartz MW. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol 2003 Jan; 24 (1): 1-10
15. Campfield LA, Smith FJ, Mackie G, et al. Insulin normalization as an approach to the pharmacological treatment of obesity. Obes Res 1995 Nov; 3 Suppl. 4: S591-603
16. Strowski MZ, Kohler M, Chen HY, et al. Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol Endocrinol 2003 Jan; 17 (1): 93-106
17. Hansen JB, Arkhammar PO, Bodvarsdottir TB, et al. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr Med Chem 2004 Jun; 11 (12): 1595-615
18. Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2003 Jun; 88 (6): 2586-92
19. Lustig RH, Greenway F, Velasquez-Mieyer P, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond) 2006 Feb; 30 (2): 331-41
20. Boehm BO, Lustig RH. Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract Res Clin Gastroenterol 2002 Jun; 16 (3): 493-509
21. Mlinar B, Marc J, Janez A, et al. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 2007 Jan; 375 (1-2): 20-35
22. Rizza RA, Mandarino LJ, Genest J, et al. Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 1985 Feb; 28 (2): 70-5
23. Sigal RJ, El-Hashimy M, Martin BC, et al. Acute postchallenge hyperinsulinemia predicts weight gain: a prospective study. Diabetes 1997 Jun; 46 (6): 1025-9
24. Le Stunff C, Bougneres P. Early changes in postprandial insulin secretion, not in insulin sensitivity, characterize juvenile obesity. Diabetes 1994 May; 43 (5): 696-702
25. Howard BV, Klimes I, Vasquez B, et al. The antilipolytic action of insulin in obese subjects with resistance to its glucoregulatory action. J Clin Endocrinol Metab 1984 Mar; 58 (3): 544-8
26. Schade DS, Eaton RP. Dose response to insulin in man: differential effects on glucose and ketone body regulation. J Clin Endocrinol Metab 1977 Jun; 44 (6): 1038-53
27. Frayn KN, Karpe F, Fielding BA, et al. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord 2003 Aug; 27 (8): 875-88
28. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science 2005 Mar; 307 (5717): 1909-14
29. Pinkney J, Wilding J, Williams G, et al. Hypothalamic obesity in humans: what do we know and what can be done? Obes Rev 2002 Feb; 3 (1): 27-34
30. Inoue S, Bray GA. An autonomic hypothesis for hypothalamic obesity. Life Sci 1979 Aug; 25 (7): 561-6
31. Bray GA, York DA. The MONA LISA hypothesis in the time of leptin. Recent Prog Horm Res 1998; 53: 95-117
32. King BM, Frohman LA. The role of vagally-medicated hyperinsulinemia in hypothalamic obesity. Neurosci Biobehav Rev 1982; 6 (2): 205-14
33. Gurrath M. Peptide-binding G protein-coupled receptors: new opportunities for drug design. Curr Med Chem 2001 Nov; 8 (13): 1605-48
34. 2+ channels in the beta cell. J Biol Chem 1991 Jan; 266 (2): 837-43
35. Bertoli A, Magnaterra R, Borboni P, et al. Dose-dependent effect of octreotide on insulin secretion after OGTT in obesity. Horm Res 1998; 49 (1): 17-21
36. Giustina A, Bussi AR, Pizzocolo G, et al. Acute effects of octreotide, a long-acting somatostatin analogue, on the insulinemic and glycemic responses to a mixed meal in patients with essential obesity: a dose-response study. Diabetes Nutr Metab 1994; 7: 735-41
37. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide: results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991 Aug; 151 (8): 1573-8
38. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994 Jun; 130 (6): 581-6
39. Baldelli R, Battista C, Leonetti F, et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 2003 Oct; 59 (4): 492-9
40. Hizuka N. Divergent effects of octreotide on glucose tolerance in patients with acromegaly. Intern Med 1997 May; 36 (5): 319-20
41. Lamers CB. Clinical and pathophysiological aspects of somatostatin and the gastrointestinal tract. Acta Endocrinol Suppl (Copenh) 1987; 286: 19-25
42. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR): a review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53 (4): 681-99
43. Barkan AL, Dimaraki EV, Jessup SK, et al. Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. J Clin Endocrinol Metab 2003 May; 88 (5): 2180-4
44. Foxx-Orenstein A, Camilleri M, Stephens D, et al. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003 Nov; 52 (11): 1555-61
45. Cremonini F, Camilleri M, Gonenne J, et al. Effect of somatostatin analog on postprandial satiation in obesity. Obes Res 2005 Sep; 13 (9): 1572-9
46. Lotter EC, Krinsky R, McKay JM, et al. Somatostatin decreases food intake of rats and baboons. J Comp Physiol Psychol 1981 Apr; 95 (2): 278-87
47. Levine AS, Morley JE. Peripherally administered somatostatin reduces feeding by a vagal mediated mechanism. Pharmacol Biochem Behav 1982 Jun; 16 (6): 897-902
48. Campbell RM, Scanes CG. Inhibition of growth hormone-stimulated lipolysis by somatostatin, insulin, and insulin-like growth factors (somatomedins) in vitro. Proc Soc Exp Biol Med 1988 Dec; 189 (3): 362-6
49. Bray GA, Gallagher TF. Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine 1975 Jul; 54 (4): 301-30
50. Karavitaki N, Cudlip S, Adams CB, et al. Craniopharyngiomas. Endocr Rev 2006 Jun; 27 (4): 371-97
51. Bunin GR, Surawicz TS, Witman PA, et al. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998 Oct; 89 (4): 547-51
52. Muller HL, Emser A, Faldum A, et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab 2004 Jul; 89 (7): 3298-305
53. Ahmet A, Blaser S, Stephens D, et al. Weight gain in craniopharyngioma: a model for hypothalamic obesity. J Pediatr Endocrinol Metab 2006 Feb; 19 (2): 121-7
54. Clement K. Genetics of human obesity. C R Biol 2006 Aug; 329 (8): 608-22
55. Goldstone AP. The hypothalamus, hormones, and hunger: alterations in human obesity and illness. Prog Brain Res 2006; 153: 57-73
56. Zhang S, Bertrais S, Hercberg S, et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab 2006 May; 91 (5): 1811-8
57. Lustig RH. Obesity in childhood cancer survivors. Pediatr Endocrinol Rev 2006 Apr; 3 Suppl. 2: 306-11
58. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008 Feb; 18 (2): 158-68
59. Preeyasombat C, Bacchetti P, Lazar AA, et al. Racial and etiopathologic dichotomies in insulin hypersecretion and resistance in obese children. J Pediatr 2005 Apr; 146 (4): 474-81
60. Danielsson P, Janson A, Norgren S, et al. Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. J Clin Endocrinol Metab 2007 Nov; 92 (11): 4101-6
61. Hoybye C, Hilding A, Jacobsson H, et al. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2003 May; 58 (5): 653-61
62. Geffner M, Lundberg M, Koltowska-Haggstrom M, et al. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database). J Clin Endocrinol Metab 2004 Nov; 89 (11): 5435-40
63. Smith DK, Sarfeh J, Howard L. Truncal vagotomy in hypothalamic obesity. Lancet 1983 Jun; I (8337): 1330-1
64. Fobi MA. Operations that are questionable for control of obesity. Obes Surg 1993 May; 3 (2): 197-200
65. Lustig RH, Rose SR, Burghen GA, et al. Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr 1999 Aug; 135 (2 Pt 1): 162-8
66. Nicholls RD, Saitoh S, Horsthemke B. Imprinting in Prader-Willi and Angelman syndromes. Trends Genet 1998 May; 14 (5): 194-200
67. Holland AJ, Treasure J, Coskeran P, et al. Measurement of excessive appetite and metabolic changes in Prader-Willi syndrome. Int J Obes Relat Metab Disord 1993 Sep; 17 (9): 527-32
68. Cummings DE, Clement K, Purnell JQ, et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 2002 Jul; 8 (7): 643-4
69. Norrelund H, Hansen TK, Orskov H, et al. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin Endocrinol (Oxf) 2002 Oct; 57 (4): 539-46
70. Silva AP, Bethmann K, Raulf F, et al. Regulation of ghrelin secretion by somatostatin analogs in rats. Eur J Endocrinol 2005 Jun; 152 (6): 887-94
71. Haqq AM, Stadler DD, Rosenfeld RG, et al. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2003 Aug; 88 (8): 3573-6
72. Tan TM, Vanderpump M, Khoo B, et al. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocr Metabol 2004 Aug; 89 (8): 4162-5
73. Goldstone AP, Thomas EL, Brynes AE, et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab 2001 Sep; 86 (9): 4330-8
74. Kennedy L, Bittel DC, Kibiryeva N, et al. Circulating adiponectin levels, body composition and obesity-related variables in Prader-Willi syndrome: comparison with obese subjects. Int J Obes Relat Metab Disord 2006 Feb; 30 (2): 382-7
75. Goldstone AP, Patterson M, Kalingag N, et al. Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 2005 May; 90 (5): 2681-90
76. Holsen LM, Zarcone JR, Brooks WM, et al. Neural mechanisms underlying hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring) 2006 Jun; 14 (6): 1028-37
77. Hinton EC, Holland AJ, Gellatly MS, et al. Neural representations of hunger and satiety in Prader-Willi syndrome. Int J Obes (Lond) 2006 Feb; 30 (2): 313-21
78. Velasquez-Mieyer PA, Cowan PA, Arheart KL, et al. Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults. Int J Obes Relat Metab Disord 2003 Feb; 27 (2): 219-26
79. Velasquez-Mieyer PA, Umpierrez GE, Lustig RH, et al. Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. Int J Obes Relat Metab Disord 2004 Feb; 28 (2): 330-3
80. Prelevic GM, Wurzburger MI, Balint-Peric L, et al. Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome. Metabolism 1992 Sep; 41 Suppl. 2: 76-9
81. Gambineri A, Patton L, De Iasio R, et al. Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. J Clin Endocrinol Metab 2005 Jul; 90 (7): 3854-62
82. Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol 2006 Jul; 86 Suppl. 1: S28-9
83. Lustig RH, Mietus-Snyder ML, Bacchetti P, et al. Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children. J Pediatr 2006 Jan; 148 (1): 23-9